Amgen to pay $762M in improper drug marketing
Drug maker Amgen will pay $762 million to settle litigation that accuses the drugmaker of marketing the anemia drug Aranesp for unapproved uses. A law firm involved in the case says the Thousand Oaks, Calif., company will pay a $612 million civil settlement, $136 million in criminal fines and a $14 million forfeiture. Credit: Handout
Amgen will pay $762 million to settle litigation that accuses the drugmaker of marketing the anemia drug Aranesp for unapproved uses.
A law firm involved in the case says the Thousand Oaks, Calif., company will pay a $612 million civil settlement, $136 million in criminal fines and a $14 million forfeiture.
Amgen develops biologic medicines, or drugs produced by living cells rather than by mixing chemicals. Its settlement marks the latest between the U.S. Department of Justice and a drugmaker over improper marketing allegations.
Doctors can prescribe drugs for unapproved uses, but companies aren't allowed to market drugs for those uses.
Nassau fails to comply with ICE deadline ... What's in NUMC's future? ... Remembering Dolly Parton ... Explore the Cold Spring Harbor Fish Hatchery
Nassau fails to comply with ICE deadline ... What's in NUMC's future? ... Remembering Dolly Parton ... Explore the Cold Spring Harbor Fish Hatchery
